Search for: "PREFERRED PHARMACEUTICALS, INC" Results 161 - 180 of 431
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
6 May 2013, 6:00 am by Rebecca Shafer, J.D.
  Author Rebecca Shafer, JD, President of Amaxx Risk Solutions, Inc. is a national expert in the field of workers compensation. [read post]
29 Apr 2014, 1:39 pm by Barry Barnett
The Supreme Court today granted certiorari in Teva Pharmaceuticals USA, Inc. v. [read post]
23 Dec 2011, 6:30 am by Sarah Tran
Prometheus Laboratories, Inc., on the counterclaim provision of the Hatch-Waxman Act in Caraco Pharmaceutical Laboratories, Ltd. v. [read post]
15 Dec 2013, 4:00 am by Administrator
Pharmaceuticals: GenericsKatz Group Canada Inc. [read post]
19 Jan 2024, 4:00 am by Alan Macek
Whereas [Biogen Canada Inc v Taro Pharmaceuticals Inc, 2020 FC 621] suggests that something more than a mere unity of invention objection from the patent examiner is required in order for the divisional application to constitute a forced divisional application. [245] The preferred approach is an informed middle ground. [read post]
13 Nov 2014, 5:00 am
  Nor was anything defective about the FDA’s preferred more than “1%” statistical format. [read post]
7 Feb 2011, 9:24 am by David Lat
Since their arrival, this group has built a leading technology M&A and licensing practice and counts among its clients Alibaba.com, Applied Materials, Dell, eBay, Hewlett-Packard, Merz Pharmaceuticals, Onyx Pharmaceuticals, Qualcomm, Riverbed, SANYO Electric, Sony, Synopsys and Zynga.Biographies for the partners and counsel accompanying Mr. [read post]
1 Nov 2011, 7:33 am by Cal Warriner
  The operator measures the pharmaceutical’s radioactivity with a dosimeter-like device, and the saline carrying the Rubidium-82 then works its way into a patient syringe. [read post]
1 Nov 2011, 7:33 am by Cal Warriner
  The operator measures the pharmaceutical’s radioactivity with a dosimeter-like device, and the saline carrying the Rubidium-82 then works its way into a patient syringe. [read post]
9 May 2017, 4:42 am
Arnold J. reiterated his view (expressed previously in Teva UK Ltd v Gilead Sciences Inc [2017] EWHC 13 (Pat)) that the test in Lilly remains unclear. [read post]